证券代码：603811 证券简称：诚意药业 公告编号：2025-009 浙江诚意药业股份有限公司 第四届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 1、浙江诚意药业股份有限公司（以下简称"公司"）第四届董事会第十三次会议 于 2025 年 4 月 28 日在洞头制造部研发大楼会议室（温州市洞头区化工路 118 号）以 现场方式召开。 2、本次会议通知和材料于 2025 年 4 月 18 日以电话及邮件等方式发送全体董事、 监事和高级管理人员。 3、本次会议应参加董事9人，实际参加董事9人。 4、本次会议由董事长颜贻意主持，公司监事、高级管理人员、证券事务代表、董 秘助理、审计部经理、投资部经理列席了本次会议。 5、本次会议召开符合《中华人民共和国公司法》和《浙江诚意药业股份有限公司 章程》等有关规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过《2024 年度董事会工作报告》 表决结果：9 票同意；0 票反对；0 票弃权。 本议案尚需提交股东大会审议。 2、审 ...

证券代码：603811 证券简称：诚意药业 公告编号：2025-011 浙江诚意药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●每股分配比例：每股派发现金股利 0.25 元（含税）。 ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。公司因股份回购产生的库存股不参与本次利润分 配。 ●在实施权益分派的股权登记日前公司总股本或库存股发生变动的，拟维持 现金派发每股分配比例不变，相应调整分配总额，并将在相关公告中披露。 ●公司不触及《上海证券交易所股票上市规则》（以下简称《股票上市规则》） 第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 根据中汇会计师事务所（特殊普通合伙）出具的标准无保留意见审计报告 ——中汇会审[2025] 2946 号，截至 2024 年 12 月 31 日母公司报表期末未分配 利润为 751,305,084.94 ...

关于浙江诚意药业股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 目 录 | | 页 次 | | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 审核说明 | 1-2 | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | 3-4 | 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zh ...

浙江诚意药业股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行在 " www.zhcpa.cn 内部控制审计报告 中汇会审[2025]2948号 浙江诚意药业股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了浙江诚意药业股份有限公司(以下简称诚意药业公司)2024年12月31日的 财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制 评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是诚意药业 公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 185,591,983.95, representing a 21.26% increase compared to CNY 153,058,271.42 in the same period last year[4] - Net profit attributable to shareholders increased by 40.10% to CNY 45,793,170.61 from CNY 32,684,974.03 year-on-year[4] - Basic and diluted earnings per share both rose by 40.00% to CNY 0.14 from CNY 0.10[4] - Operating profit for Q1 2025 was ¥53,738,813.23, up 43.4% from ¥37,509,072.47 in Q1 2024[21] - Net profit for Q1 2025 was ¥46,868,712.96, representing a 43.2% increase from ¥32,730,039.82 in Q1 2024[21] - Earnings per share for Q1 2025 was ¥0.14, compared to ¥0.10 in Q1 2024[22] Cash Flow - The net cash flow from operating activities surged by 589.62% to CNY 55,507,117.33, up from CNY 8,048,893.69 in the previous year[4] - Cash flow from operating activities for Q1 2025 was ¥55,507,117.33, significantly higher than ¥8,048,893.69 in Q1 2024[25] - The company reported a net cash outflow from investing activities of ¥9,687,122.47 in Q1 2025[25] - Total cash inflow from financing activities amounted to $1,000,000.00, while cash outflow totaled $47,227,623.22, resulting in a net cash flow of -$46,227,623.22[27] - The net increase in cash and cash equivalents was -$558,340.99, with a beginning balance of $169,447,913.66, leading to an ending balance of $168,889,572.67[27] - The cash flow from financing activities showed a significant increase in outflows compared to the previous period, which had outflows of $30,708,485.27[27] - The impact of exchange rate changes on cash and cash equivalents was -$150,712.63[27] Assets and Liabilities - Total assets decreased by 2.79% to CNY 1,680,186,414.91 from CNY 1,728,380,749.86 at the end of the previous year[5] - Total liabilities decreased from ¥463,314,446.90 in the previous period to ¥376,106,697.83[18] - Current liabilities decreased to ¥226,284,989.18 from ¥291,503,720.47, a decrease of about 22.4%[17] - Long-term borrowings decreased to ¥118,508,000.00 from ¥139,308,000.00, a reduction of approximately 14.9%[17] Shareholder Information - The total number of shareholders at the end of the reporting period is 16,520[11] - The largest shareholder, Yan Yiyi, holds 77,192,080 shares, representing 23.58% of the total shares[11] - The company has a total of 4,000,000 shares held by Yan Maolin through a credit securities account[12] - There are no significant changes in the participation of major shareholders in margin financing and securities lending activities[12] Research and Development - Research and development expenses decreased by 34.97%, mainly due to reduced outsourcing and personnel costs[8] - Research and development expenses for Q1 2025 were ¥7,660,759.12, down from ¥11,781,100.15 in Q1 2024[21] Other Financial Metrics - The weighted average return on equity increased by 0.87 percentage points to 3.57% compared to 2.70% at the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 3.01% to CNY 1,298,022,359.19 from CNY 1,260,084,487.42[5] - Accounts receivable increased to ¥39,679,124.70 from ¥32,909,369.27, indicating a growth of approximately 20.5%[16] - Inventory decreased to ¥118,406,392.38 from ¥131,843,548.31, a decline of about 10.2%[16] - The company recognized a government subsidy of CNY 868,215.62, which is expected to have a continuous impact on its profits[6] - Sales expenses increased to ¥43,626,154.81 in Q1 2025 from ¥39,746,999.05 in Q1 2024[21] Accounting Standards - The company did not apply new accounting standards starting from 2025[27]

Financial Performance - The company's operating revenue for 2024 reached RMB 714,369,070.89, representing a 6.36% increase compared to RMB 671,626,943.73 in 2023[24]. - Net profit attributable to shareholders for 2024 was RMB 200,700,773.72, a 23.21% increase from RMB 162,896,651.50 in 2023[24]. - The net cash flow from operating activities for 2024 was RMB 205,715,849.04, reflecting a 5.61% increase from RMB 194,780,877.43 in 2023[24]. - Total assets at the end of 2024 were RMB 1,728,380,749.86, a decrease of 8.68% from RMB 1,892,765,912.73 at the end of 2023[25]. - The net assets attributable to shareholders increased to RMB 1,260,084,487.42, up 5.68% from RMB 1,192,314,263.44 at the end of 2023[25]. - Basic earnings per share increased by 22.00% to CNY 0.61 compared to CNY 0.50 in 2023[26]. - The company reported a decrease of 18.06% in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to RMB 126,863,340.37 in 2024[24]. - Net profit attributable to shareholders rose by 6.36% due to increased operating revenue and asset disposal gains from Jiangsu Chengyi[27]. - Net profit excluding non-recurring gains decreased by 17.02% to CNY 0.39 per share, attributed to declining investment income and increased losses from subsidiary San Da Yuan[26][27]. Cash Flow and Investments - The company reported a net cash flow from operating activities of CNY 205,685,928.34 for the year, with a notable increase in Q4 to CNY 100,731,581.70[29]. - The net cash flow from investing activities improved significantly to CNY 26,181,722.11, compared to a negative cash flow of CNY -59,600,658.72 in the previous year, primarily from the sale of fixed assets by a subsidiary[54]. - The company experienced a 55.92% increase in taxes and surcharges, totaling CNY 14,329,993.19, due to higher property and value-added taxes[54]. Market and Product Development - The main product, glucosamine hydrochloride capsules, secured over 41% market share in 9 provinces after winning the national procurement bid in August 2020, with the procurement period ending in October 2023[42]. - The company is actively communicating with provincial institutions for contract renewals to maintain market share and has expanded sales through national procurement across 30 provinces[42]. - New product developments include the successful approval of bone calcitriol soft capsules and levocarnitine injection, with ongoing consistency evaluations for lidocaine injection and amikacin sulfate injection[40]. - The company plans to enhance product research and development, focusing on anti-tumor and liver protection drugs to diversify its product line[48]. - The company has established long-term stable partnerships with well-known pharmaceutical companies, facilitating further cooperation in raw material production[48]. - The company is focusing on high-end small varieties of "marine drugs" and "major disease medications" to drive future growth[103]. Research and Development - The company has over 30 products in development, focusing on marine drugs, geriatric medications, and anti-tumor drugs[88]. - The company holds 21 valid authorized invention patents, with 5 products recognized as "Excellent Industrial Products" in Zhejiang Province[88]. - The company has initiated consistency evaluation for 9 oral solid preparations, with one key product approved[89]. - The company plans to increase investment in drug research and development and strengthen cooperation with research institutions[90]. - The company reported a research and development (R&D) investment of 6.59% of operating revenue, which is lower than the industry average of 7.14%[98]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights and interests[123]. - There are no reported instances of the controlling shareholder interfering with the company's decision-making processes, maintaining operational independence[124]. - The company has implemented strict information disclosure practices to enhance transparency and prevent insider trading, thereby protecting shareholder rights[126]. - The company is committed to improving its governance structure and internal control mechanisms to ensure sustainable development[126]. - The company has not faced any regulatory requirements for rectification regarding its governance practices[126]. Environmental Responsibility - The company has not experienced any environmental pollution incidents or exceeded discharge limits during the reporting period[167]. - The company has established a comprehensive emergency response plan for environmental incidents, which was approved by the local environmental bureau in December 2024[185]. - The company has implemented carbon reduction measures, successfully reducing CO2 equivalent emissions by 537 tons[188]. - The company has committed to avoiding any competitive actions that could harm the interests of Kang Le Pharmaceutical, ensuring compliance with all relevant regulations[190]. Employee and Management Structure - The total employee compensation for the company reached 99,356,459, with an average of 1,124.33 per employee[130]. - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including positions in various pharmaceutical companies and associations[131]. - The company has a diverse board of directors with expertise in finance, law, and pharmaceuticals, which supports its strategic decision-making[132]. - The performance evaluation mechanism for senior management includes a salary structure of "annual salary + annual performance bonus," with 30% of the salary reserved and linked to sales and net profit targets[162].

浙江诚意药业股份有限公司 2024 年度审计报告 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 证明该审计报告是否由具有执业许可的会计师事务所出 "注册会 您可使用手机"扫一扫"或进入 c.mof.gov.cn） 报告编码: 浙25RFS = (http:/ 一、审计报告 1-5 二、财务报表 6-17 (一) 合并资产负债表 6-7 (二) 合并利润表 (三) 合并现金流量表 (四) 合并所有者权益变动表 10-11 (五) 母公司资产负债表 12-13 (六) 母公司利润表 14 (七) 母公司现金流量表 15 (八) 母公司所有者权益变动表 16-17 三、财务报表附注 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and ...

Core Viewpoint - Chengyi Pharmaceutical (603811) has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient, Dobutamine Hydrochloride, which is used in the treatment of cardiovascular diseases [1] Group 1: Product Approval - The approved active pharmaceutical ingredient is a β-adrenergic agonist that stimulates cardiac β1 receptors, enhancing myocardial contractility while dilating peripheral blood vessels and reducing cardiac load [1] - Current domestic manufacturers include Zhejiang Ruixin Pharmaceutical and Shanghai Ziyuan Pharmaceutical [1] Group 2: R&D Investment - The company has invested approximately 5.1982 million yuan in the research and development of this active pharmaceutical ingredient [1] Group 3: Business Impact - The approval will enrich the company's product line and help expand its business scope, although it is not expected to have a significant impact on current performance [1]

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]

3、规格：25 片/瓶 证券代码： 603811 证券简称： 诚意药业 公告编号：2025-008 一、 概况 浙江诚意药业股份有限公司（以下简称"公司"或"诚意药业"）于近日收到国 家药品监督管理局（以下简称"国家药监局"）核准签发的巯嘌呤片《药品注册证书》， 现将具体情况公告如下： 浙江诚意药业股份有限公司 关于巯嘌呤片获得药品注册证书的公告 1、药品名称： 巯嘌呤片 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 2、剂型：片剂 4、证书编号：2025S00948 5、药品注册标准编号：YBH06702025 6、申请事项：药品注册(境内生产) 7、注册分类：化学药品 3 类 8、药品有效期：24 个月 9、药品批准文号：国药准字 H20253809 10、药品批准文号有效期：至 2030 年 4 月 7 日 11、生产企业名称：浙江诚意药业股份有限公司 12、生产企业地址：浙江省温州市洞头区化工路 118 号 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合 药品注 册的有关要求，批准注册，发给药 ...